CD200 and myeloid sarcoma: One of the mechanisms of action by which β-interferon elicits its beneficial effect in MS patients appears to be by its ability to inhibit astrocytic NO production [21], and thereby decreasing the availability of circulatory RNS that have the potential to induce MRC impairment, particularly at the level of complex IV.